Need professional-grade analysis? Visit stockanalysis.com
$49.72M
0.04
6
N/A
Prostatype Genomics AB (PROGEN) trades on Nasdaq Stockholm in SEK. The company is classified in the Healthcare sector under the Diagnostics & Research industry. The stock currently trades at SEK0.79, up 5.07% from the previous close.
Over the past year, PROGEN has traded between a low of SEK0.30 and a high of SEK1.95. The stock has lost 58.1% over this period. It is currently 59.5% below its 52-week high.
Prostatype Genomics AB has a market capitalization of $49.72M, with a price-to-earnings ratio of 0.04.
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors when making a treatment decision. The company was incorporated in 2007 and is headquartered in Solna, Sweden.
Side-by-side comparison against top Healthcare peers.